.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
US Department of Justice
Queensland Health
UBS
Chubb
Teva
Daiichi Sankyo
Fuji
Julphar
Moodys

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,615,573

« Back to Dashboard

Which drugs does patent 7,615,573 protect, and when does it expire?


Patent 7,615,573 protects CERDELGA and is included in one NDA.

This patent has twenty-nine patent family members in thirteen countries.

Summary for Patent: 7,615,573

Title:Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
Inventor(s): Siegel; Craig (Woburn, MA), Shayman; James A. (Ann Arbor, MI), Nelson; Carol A. (Westford, MA), Harris; David J. (Lexington, MA), Copeland; Diane P. (North Billerica, MA)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI) Genzyme Corporation (Cambridge, MA)
Application Number:11/702,425
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genzyme CorpCERDELGAeliglustat tartrateCAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► SubscribeTREATMENT OF GAUCHER DISEASE TYPE 1► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,615,573

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,546,161Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors► Subscribe
6,855,830 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
8,779,163Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors► Subscribe
7,763,738Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
8,138,353Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
7,265,228Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
7,196,205Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,615,573

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2010095546► Subscribe
Japan5227348► Subscribe
Japan2017075151► Subscribe
Japan2005255686► Subscribe
Japan4708073► Subscribe
Japan2005502635► Subscribe
Japan5038582► Subscribe
Israel193244► Subscribe
Israel159905► Subscribe
Hong Kong1153733► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
Citi
Queensland Health
Dow
Novartis
Cantor Fitzgerald
McKinsey
Deloitte
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot